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o r i g i n a l a r t i c l e
Economic Impact of Ventilator-Associated Pneumonia
in a Large Matched Cohort
Marin H. Kollef, MD;1 Cindy W. Hamilton, PharmD;2 Frank R. Ernst, PharmD, MS3
objective. To evaluate the economic impact of ventilator-associated pneumonia (VAP) on length of stay and hospital costs.
design. Retrospective matched cohort study.
setting. Premier database of hospitals in the United States.
patients. Eligible patients were admitted to intensive care units (ICUs), received mechanical ventilation for ≥2 calendar-days, and were
discharged between October 1, 2008, and December 31, 2009.
methods. VAP was defined by International Classification of Diseases, Ninth Revision (ICD-9), code 997.31 and ventilation charges for
≥2 calendar-days. We matched patients with VAP to patients without VAP by propensity score on the basis of demographics, administrative
data, and severity of illness. Cost was based on provider perspective and procedural cost accounting methods.
results. Of 88,689 eligible patients, 2,238 (2.5%) had VAP; the incidence rate was 1.27 per 1,000 ventilation-days. In the matched
cohort, patients with VAP ( ) had longer mean durations of mechanical ventilation (21.8 vs 10.3 days), ICU stay (20.5 vs 11.6np 2,144
days), and hospitalization (32.6 vs 19.5 days; all ) than patients without VAP ( ). Mean hospitalization costs were $99,598P ! .0001 np 2,144
for patients with VAP and $59,770 for patients without VAP ( ), resulting in an absolute difference of $39,828. Patients with VAPP ! .0001
had a lower in-hospital mortality rate than patients without VAP (482/2,144 [22.5%] vs 630/2,144 [29.4%]; ).P ! .0001
conclusions. Our findings suggest that VAP continues to occur as defined by the new specific ICD-9 code and is associated with a
statistically significant resource utilization burden, which underscores the need for cost-effective interventions to minimize the occurrence
of this complication.
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Ventilator-associated pneumonia (VAP) is of concern because
of its frequency and economic burden. Pneumonia is the most
common discharge diagnosis in the United States.1 Between
1997 and 2008, use of respiratory intubation and mechanical
ventilation (MV) escalated, and the cost of respiratory failure
grew at 2–3 times those of total hospital costs.1 Cost is relevant
to providers because VAP is among the conditions being con-
sidered for nonreimbursement by the Centers for Medicare
and Medicaid Services.
VAP prolongs length of stay (LOS) and increases hospital
costs;2-5 however, estimates are derived from data collected
between the mid-1980s and 2004 and may not reflect the
impact of inflation. On the other hand, estimates may not
reflect the impact of economic pressure to minimize LOS or
use new preventive strategies. In addition, previous studies
often relied on nonspecific diagnostic criteria, such as the use
of MV and the diagnostic code for bacterial pneumonia.
We hypothesized that VAP—as defined by the specific In-
ternational Classification of Diseases, Ninth Revision, clinical
modification (ICD-9) code 997.31 introduced in 2008—would
be associated with increased LOS and hospital costs. To test
this hypothesis, we performed a matched cohort study of the
Premier database and evaluated the impact of VAP on LOS in
the hospital and intensive care unit (ICU), duration of MV,
and hospital costs. We also calculated the frequency of VAP
and in-hospital mortality.
methods
To evaluate the economic impact of VAP on hospitals, we
performed a retrospective matched cohort study of the Premier
research database, which involves approximately 400 of 12,500
hospitals in the Premier healthcare alliance. The study was
conducted in compliance with US federal regulations, the
Health Insurance Portability and Accountability Act, and the
Helsinki Declaration. Patient-specific data were deidentified.
To be included in the study, adults (age ≥18 years) had to
have spent at least 1 day in the ICU and to have been dis-
table 1. Demographic, Admission, and Discharge Data









(N p 2,144) P
Age, years !.0001
18–44 459 (20.5) 11,730 (13.6) 412 (19.2) 404 (18.8)
45–64 860 (38.4) 31,360 (36.3) 831 (38.8) 850 (39.7)
65–79 669 (29.9) 28,515 (33.0) 653 (30.5) 651 (30.4)
≥80 250 (11.2) 14,846 (17.2) 248 (11.6) 239 (11.2)
Mean  SD 62.9  16.6 58.8  17.5 59.3  17.3 59.4  17.1
Sex, male 1,415 (63.2) 46,642 (54.0) !.0001 1,337 (62.4) 1,335 (62.3)
Race !.0001
White 1,343 (60.0) 54,351 (62.3) 1,311 (61.2) 1,332 (62.1)
Black 432 (19.3) 13,310 (15.4) 406 (18.9) 408 (19.0)
Hispanic 159 (7.1) 4,088 (4.7) 133 (6.2) 122 (5.7)
Other/unknown 304 (13.6) 14,702 (17.0) 294 (13.7) 282 (13.2)
Primary payor !.0001
Medicare 1,044 (46.7) 49,150 (56.9) 1,027 (47.9) 1,028 (48.0)
Medicaid 391 (17.5) 10,402 (12.0) 364 (17.0) 363 (16.9)
Managed care 399 (17.8) 13,185 (15.3) 383 (17.9) 397 (18.5)
Commercial 171 (7.6) 5,176 (6.0) 159 (7.4) 150 (7.0)
Other 233 (10.4) 8,538 (9.9) 211 (9.8) 206 (9.6)
Admission source !.0001
Physician referral 329 (14.7) 13,223 (15.3) 319 (14.9) 296 (13.8)
Transfer from another health facility 532 (23.8) 14,883 (17.2) 496 (23.1) 489 (22.8)
Emergency room 1,293 (57.8) 57,109 (66.1) 1,257 (58.6) 1,293 (60.3)
Other or unknown 84 (3.8) 1,236 (1.4) 72 (3.4) 66 (3.1)
Admission type !.0001
Emergency 1,558 (69.6) 62,277 (72.0) 1,517 (70.8) 1,554 (72.5)
Urgent 317 (14.2) 12,697 (14.7) 310 (14.5) 291 (13.6)
Elective 239 (10.7) 9,348 (10.8) 226 (10.5) 209 (9.8)
Trauma center/other/unknown 124 (5.5) 2,129 (2.5) 91 (4.2) 90 (4.2)
Discharge status !.0001 !.0001
Expired 498 (22.3) 25,053 (29.0) 482 (22.5) 630 (29.4)
Transferred to home 378 (16.9) 23,177 (26.8) 356 (16.6) 561 (26.2)
Transferred to skilled nursing facility 440 (19.7) 14,737 (17.1) 426 (19.9) 366 (17.1)
Transferred to rehab 273 (12.2) 6,492 (7.5) 260 (12.1) 191 (8.9)
Transferred to short-term hospital 153 (6.8) 4,409 (5.1) 149 (7.0) 82 (3.8)
Other or unknown 496 (22.2) 12,583 (14.6) 471 (22.0) 314 (14.6)
APR-DRG severity of illness !.0001
Minor or moderate 3 (0.1) 1,337 (1.5) 3 (0.1) 2 (0.1)
Major 116 (5.2) 9,828 (11.4) 112 (5.2) 99 (4.6)
Extreme 2,119 (94.7) 75,286 (87.1) 2,029 (94.6) 2,043 (95.3)
APR-DRG risk of mortality !.0001
Minor or moderate 71 (3.2) 4,670 (5.4) 62 (2.9) 41 (1.9)
Major 538 (24.0) 19,797 (22.9) 499 (23.3) 490 (22.9)
Extreme 1,629 (72.8) 61,984 (71.7) 1,583 (73.8) 1,613 (75.2)
Geographic area !.0001
Northeast 380 (17.0) 14,596 (16.9) 362 (16.9) 357 (16.7)
Midwest 614 (27.4) 19,227 (22.2) 581 (27.1) 567 (26.5)
South 969 (43.3) 37,433 (43.3) 932 (43.5) 949 (44.3)
West 275 (12.3) 15,195 (17.6) 269 (12.6) 271 (12.6)
Urban population 168 (7.5) 8,630 (10.0) !.0001 1,979 (92.3) 1,980 (92.4)
Teaching hospital 1,478 (66.0) 41,221 (47.7) !.0001 1,388 (64.7) 1,386 (64.7)
Hospital size, beds !.0001
6–199 116 (5.2) 8,099 (9.4) 114 (5.3) 108 (5.0)
200–299 195 (8.7) 12,019 (13.9) 194 (9.1) 196 (9.1)
300–499 752 (33.6) 33,924 (39.2) 727 (33.9) 728 (34.0)
≥500 1,175 (52.5) 32,409 (37.5) 1,109 (51.7) 1,112 (51.9)
note. Data are number of discharges (%), unless otherwise indicated. APR-DRG, all patient refined diagnosis-related group;
SD, standard deviation; VAP, ventilator-associated pneumonia.
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table 2. Diagnostic Codes in All Patients
No. of discharges (%)





3 ECMO or tracheostomy with mechanical
ventilation ≥96 h or principal diagnosis
except face, mouth, and neck with ma-
jor OR
MS-DRG 3: trach with MV ≥96 h with
major OR
658 (29.4) 7,005 (8.1)
4 Tracheostomy with mechanical ventilation
≥96 h or principal diagnosis except
face, mouth, and neck without major
OR
MS-DRG 4: trach with MV ≥96 h with-
out major OR
372 (16.6) 6,100 (7.1)
207 Respiratory system diagnosis with ventila-
tor support ≥96 h
MS-DRG 207: respiratory diagnosis with
MV ≥96 h
232 (10.4) 9,898 (11.4)
870 Septicemia or severe sepsis with mechani-
cal ventilation ≥96 h
MS-DRG 870: sepsis with MV ≥96 h 177 (7.9) 6,572 (7.6)
853 Infectious and parasitic diseases with OR
with major complication or
comorbidity
MS-DRG 853: infection with OR and
major complication
47 (2.1) 2,927 (3.4)
208 Respiratory system diagnosis with ventila-
tor support !96 h
MS-DRG 208: respiratory diagnosis with
MV !96 h
39 (1.7) 9,782 (11.3)
329 Major small and large bowel procedure
with major complication or
comorbidity
MS-DRG 329: bowel procedure with ma-
jor complication
35 (1.6) 2,480 (2.9)
note. ECMO, extracorporeal membrane oxygenation; MS-DRG, Medicare severity diagnosis-related group; MV, mechanical ventilation;
OR, operating room procedure; trach, tracheostomy; VAP, ventilator-associated pneumonia.
charged from the hospital between October 1, 2008, and De-
cember 31, 2009. Patients on continuous MV were identified
using ICD-9 procedure codes 96.71 or 96.72; they also had
to have undergone MV for ≥2 calendar-days, as defined by
billing charges. VAP was defined by ICD-9 code 997.31.
Economic data were based on true hospital costs, including
direct and indirect medical costs (eg, fixed, variable, and over-
head costs were indirect costs from an accounting perspec-
tive); indirect costs incurred by patients and their caregivers
were excluded. ICU costs were determined using room and
board billing (eg, coronary care unit and surgical, medical,
cardiac, and cardiovascular ICUs) and did not include step-
down or telemetry units. Cost analysis proceeded from the
hospital perspective. Cost data were obtained from hospital
accounting systems and reported to Premier. Most hospitals
used procedural cost accounting methods; ≤25% used ratios
of costs to charges and total patient-level charges. Actual costs
were available for each revenue department as well as for each
billing item. Patient billing codes for products and services
received during hospitalization were captured. In-hospital
mortality was indicated by a discharge status of expired.
Statistical Analysis
Categorical data were expressed as percentages of patients;
between-group differences (with vs without VAP) were com-
pared using x2 or Fisher exact tests. Continuous data were
expressed as means and standard deviations; between-group
differences were compared using 1-way ANOVA. Statistical
analyses were conducted using WinSQL (Synametrics Tech-
nologies) and SAS (ver. 9.1; SAS Institute). All statistical tests
of comparison were 2 sided based on . All analysesa ! .05
were conducted for the overall VAP population as well as for
the 7 Medicare severity diagnosis-related groups (MS-DRGs)
with the highest volume of VAP patients.
Propensity score matching was used to adjust for between-
group imbalances. Logistic regression was performed to es-
timate the propensity score for each patient using available
covariates, which were selected a priori and on the basis of
ability to maximize the receiver operator characteristic curve
of the selection model. Propensity scoring was used to match
each case patient with VAP to 1 control patient without VAP,
using a greedy algorithm,6,7 which matches the highest digit
in a hierarchical sequence until each case is matched; match-
ing was performed at ≥4 digits. Patient characteristics used
in matching were age, gender, race/ethnicity, primary payor
type, attending physician specialty, admission source, admis-
sion type, 3M all patient refined (APR)-DRG severity of ill-
ness, and APR-DRG risk of mortality. Hospital characteristics
were geographic region, bed size, urban/rural status, and
teaching status.
Matching was conducted on the overall VAP population
and on the 7 MS-DRGs with the most VAP patients. Match
quality was evaluated using a quantile distribution of the
propensity scores for each population as well as univariate
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figure 1. Duration of mechanical ventilation, intensive care unit (ICU) stay, and hospital stay in a matched cohort of 2,144 patients with
ventilator-associated pneumonia (VAP) and 2,144 patients without VAP. All for between-cohort differences in durations ofP ! .0001
hospitalization, ICU stay, and mechanical ventilation.
ANOVA to test for between-group differences. Tests of com-
parison of each of patient and hospital variables were con-
ducted using the matched population to further test between-
group imbalances in covariates.
results
All Patients
Of 88,689 patients who had undergone MV for ≥2 calendar-
days, 2,238 (2.5%) had the ICD-9 code for VAP. The incidence
rate was 1.27 cases per 1,000 MV-days. Patients with VAP
were older and more likely to be male than patients without
VAP (Table 1). Patients with VAP were more likely to have
been transferred from another healthcare facility and to have
been discharged to skilled nursing or rehabilitation facilities.
Patients with VAP represented 161 different MS-DRGs, but
the 7 most common comprised 70% of all patients with VAP
(Table 2). The most common in patients with VAP was MS-
DRG 3 (29.4%; for descriptions of abbreviated diagnostic
codes, see Table 2).
Matched Cohort
A total of 2,144 case patients with VAP were matched with
2,144 control patients without VAP, representing 96% of the
VAP population. There were no between-group differences
in patient or hospital characteristics except for discharge
status, which was excluded from matching because mortality
was an outcome of interest (see Table 1). Matching captured
86%–100% of the VAP population for the 7 MS-DRG
populations.
Patients with VAP had longer durations of MV (mean 
standard deviation [SD], vs days),21.8 25.0 10.3 10.5
ICU stay ( vs days), and hospitali-20.5 15.8 11.6 10.3
zation ( vs days; all ) than32.6 31.9 19.5 17.9 P ! .0001
patients without VAP (Figure 1). At least 1 of these 3 out-
comes (duration of MV, ICU stay, or hospitalization) was
longer for patients with VAP in 6 of 7 MS-DRG populations;
the exception was MS-DRG 329 (authors’ online Table 1
available at their Web site http://hamiltonhouseva.com/
KollefVAPeconomicsICHEtables.pdf).
Patients with VAP had higher mean costs for hospitaliza-
tion, pharmacy, antibiotics, vancomycin, propofol, ventilation
both overall and in the ICU, respiratory therapy, and chest
x-rays (Table 3). For example, mean hospitalization costs were
$99,598 for patients with VAP and $59,770 for patients with-
out VAP ( ), resulting in an absolute difference ofP ! .0001
$39,828 between these matched cohorts. Mean hospitalization
costs were higher for patients with VAP than for those without
in the following MS-DRG populations: MS-DRG 4, MS-DRG
870, MS-DRG 853, and MS-DRG 207 (Table 4). Selected
costs—such as those related to antibiotic use or pharmacy as
a whole, MV, respiratory therapy, or chest x-rays—were also
higher in patients with VAP, especially in MS-DRG 4, MS-
DRG 870, and MS-DRG 853 (authors’ online Table 2
available at their Web site http://hamiltonhouseva.com/
KollefVAPeconomicsICHEtables.pdf).
Patients with VAP had a lower overall in-hospital mortality
rate than patients without VAP (482/2,144 [22.5%] vs 630/
2,144 [29.4%]; ; data not shown). There were noP ! .0001
between-group differences in 30-day all-cause readmissions,
excluding mortality (287/1,662 [17.3%] vs 271/1,514 [17.9%];
). There were no between-group differences in anyPp .64
of the MS-DRG populations except MS-DRG 853. In that
population, patients with VAP had higher rates of mortality
(19/46 [41.3%] vs 7/46 [15.2%]; ) and 30-day all-Pp .01
254 infection control and hospital epidemiology march 2012, vol. 33, no. 3
table 3. Costs in a Matched Cohort of 2,144 Patients with Ventilator-Associated Pneumonia (VAP)
and 2,144 Patients without VAP
Cost, dollars, mean  SDa
Outcome type With VAP Without VAP P Difference in dollars (%)
Hospitalization 99,598  86,359 59,770  58,278 !.0001 39,828 (40.0)
Nursing time 3,369  16,487 2,980  14,109 .568 389 (11.5)
Pharmacy 14,345  16,992 8,547  14,497 !.0001 5,798 (40.4)
Antibiotic 1,947  4,095 1,011  2,039 !.0001 936 (48.1)
Vancomycin 327  564 248  420 !.0001 79 (24.2)
Propofol for sedation 947  1,768 585  1,202 !.0001 362 (38.2)
Ventilator 4,710  6,251 2,184  2,807 !.0001 2,526 (53.6)
Ventilator in ICU 3,716  4,479 1,909  2,304 !.0001 1,807 (48.6)
Respiratory therapy 2,650  4,007 1,496  2,539 !.0001 1,154 (43.5)
Chest x-rays 1,762  1,594 1,009  958 !.0001 753 (42.7)
note. ICU, intensive care unit; SD, standard deviation.
a Costs represent medical direct and indirect costs (not Medicare charges). Costs were not additive
(eg, antibiotic and propofol costs were a subset of pharmacy costs).
cause readmissions, excluding mortality (9/46 [19.6%] vs 3/
46 [6.5%]; ).Pp .01
discussion
Our database analysis revealed VAP in 2.6% of 88,689
hospitalized patients who had undergone MV ≥2 calendar-
days. A unique feature of our study was the analysis of
VAP rate by MS-DRG population. The highest rates were
8.6% in patients with MS-DRG 3 and 5.7% in those with
MS-DRG 4, which is consistent with the prolonged duration
of MV in these populations (authors’ online Table 1
available at their Web site http://hamiltonhouseva.com/
KollefVAPeconomicsICHEtables.pdf). In patients matched by
propensity scores comprising severity of illness and other
possible confounders, VAP added approximately $40,000 to
absolute hospital costs and at least 10 days to the absolute
durations of MV, ICU stay, and overall hospitalization.
Our findings add to those of previous studies involving
large databases2,3 or literature reviews of mechanically ven-
tilated patients;4,5 however, differences in study methods may
have affected VAP rates. Rello et al2 reported that VAP oc-
curred in 9.3% of 9,080 ICU patients who had undergone
MV ≥24 hours and who had ICD-9 codes for bacterial pneu-
monia. Similarly, Safdar et al4 reported a cumulative incidence
of 9.7% in 48,112 patients in 38 cohort or nonrandomized
studies, whereas the incidence was 22.8% in 4,802 patients
in 51 randomized studies. Buczko3 reported VAP in 24.5%
of 13,759 Medicare patients in long-term care hospitals. These
between-study differences could be attributable to differences
in study populations, diagnostic criteria, use of preventive
strategies, and other factors. Our low rate is consistent with
the use of a VAP-specific code, which probably reduced the
risk of false positive identification. Alternatively, the new di-
agnostic code may have had poor sensitivity.
The LOS in our study was within the range of previous
studies involving large databases2,3 or a literature review;4 LOS
was not reported in the other literature review.5 Specifically,
the 10-day additional LOS in our study was generally con-
sistent with that in 1 of the database studies.2 VAP added 6.1
days to the mean ICU stay in the literature review.4 Not
surprisingly, LOS was prolonged for patients in long-term
care hospitals, where total LOS was 46.5 days for patients
with VAP and 43.8 days for patients without VAP.3
The incremental hospital cost of VAP was higher in our
study than in previous studies. VAP was associated with at-
tributable hospital costs of $10,000–$13,500 per 5–7 days in
a review of studies conducted between 1984 and 2002.4 In
the remaining studies, VAP was associated with additional
charges of approximately $15,000 in long-term care patients
in 20043 and of $40,000 in the database analysis conducted
in the late 1990s.2 These between-study differences are at-
tributable to timing differences, with inflation contributing
to the higher cost in our more recent study. In addition,
charges in 2 studies2,3 are inherently higher than costs in our
study and in another study.4
Another unique feature of our study was the breakdown
of costs for expense categories. Many costs were higher among
patients with VAP than among patients without VAP, espe-
cially pharmacy, MV, respiratory therapy, and chest x-
rays—all of which were at least 40% higher. The increase in
nursing time, however, was not significantly higher among
cases. Restrepo et al8 also reported higher breakdown costs
in a matched cohort study of 30 case patients and 90 control
patients. As in our study, the costs of overall hospitalization
and respiratory therapy were higher among patients with
VAP; however, between-cohort differences in pharmacy were
not statistically significant, possibly because of sample size.
Additional categories with significant between-cohort differ-
ences were cardiology, operating room, electrocardiogram,
and recovery room; we did not collect data on these
categories.
Mortality was lower in patients with VAP than patients
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table 4. Hospitalization Costs in a Matched Cohort of Patients with Ventilator-Associated Pneumonia (VAP) and Patients without VAP
Cost, dollars, mean  SDa
MS-DRG code Population With VAP Without VAP P
3 ECMO or tracheostomy with mechanical ventilation ≥96 h or
principal diagnosis except face, mouth, and neck with major
OR
153,625  105,696 142,827  125,400 .113
4 Tracheostomy with mechanical ventilation ≥96 h or principal
diagnosis except face, mouth, and neck without major OR
112,865  77,784 83,187  44,590 !.0001
207 Respiratory system diagnosis with ventilator support ≥96 h 46,928  34,145 41,627  24,701 .060
870 Septicemia or severe sepsis with mechanical ventilation ≥96 h 59,238  58,111 44,642  25,851 .005
853 Infectious and parasitic diseases with OR procedure with major
complication or comorbidity
103,082  91,291 66,972  51,444 .022
208 Respiratory system diagnosis with ventilator support !96 h 25,612  20,324 17,593  8,269 .027
329 Major small and large bowel procedure with major complication
or comorbidity
90,799  62,532 69,767  77,229 .215
note. ECMO, extracorporeal membrane oxygenation; MS-DRG, Medicare Severity diagnosis-related group; OR, operating room procedure;
SD, standard deviation.
without VAP (22.5% vs 29.4%; ), which contrastsP ! .0001
with popular perception but has been previously reported.
Only 14 of the studies involving large databases2,3 or literature
reviews4,5 revealed an association between VAP and mortality
(odds ratio [OR], 2.03 [95% confidence interval (CI),
1.16–3.56]). In the remaining studies, between-cohort dif-
ferences were not significant2,3 or mortality was not reported.5
This is not surprising in view of the results of a recent sys-
tematic review.9 The relative risk of mortality was 1.27 (95%
CI, 1.15–1.39) in a pooled analysis of 52 observational studies
of patients with and without VAP; however, considerable het-
erogeneity confounded interpretation of these findings. In-
terestingly, VAP was not associated with mortality in the only
2 populations that had limited heterogeneity, namely, trauma
(OR, 1.09 [95% CI, 0.87–1.37]) and acute respiratory distress
syndrome (OR, 0.86 [95% CI, 0.72–1.04]).9
Collectively, current and previous2-5 findings have impor-
tant clinical implications because they suggest that VAP con-
tinues to be associated with a substantial resource utilization
burden, which can be used to justify the use of preventive
strategies. In addition to reducing the incidence of VAP, the
ideal strategy should not increase healthcare costs or burden
healthcare providers.10,11 Examples of strategies shown to re-
duce the incidence of VAP and to be cost effective include
multifaceted preventive bundles,12-14 which include education,
semirecumbent positioning, good oral hygiene, and other in-
fection control practices.
Our study had several limitations. It was subject to the
inherent bias of retrospective analysis; however, the data were
collected prospectively. To limit bias, we matched patients at
the 4-digit propensity score precision level or higher. The
cohorts appeared to be balanced, as demonstrated by the lack
of differences in patient and hospital characteristics other
than discharge status. Including severity of illness as a variable
may have biased the matching process because VAP can
worsen this variable; however, this would have attenuated the
impact of VAP. The database did not include information on
preventive strategies or some risk factors for VAP, such as
supine positioning. We did not collect information on mi-
crobiology, detailed antibiotic use, or appropriateness of ini-
tial therapy and therefore could not assess the role of these
variables on outcome. We were not able to specifically link
all costs directly to VAP, such as incremental antibiotic costs.
We did not validate use of the new VAP diagnosis code against
patient charts or alternate database methods that relied on
post-MV initiation of treatment for pneumonia to identify
VAP. If the code lacked sensitivity as suggested by the low
VAP rate, our study population may not be representative of
patients with VAP; however, this limitation would have at-
tenuated the impact of VAP on economic findings. Our find-
ings do not prove that VAP caused the observed increased
LOS; it is possible that the increased duration of hospitali-
zation caused the increased risk of infection, an inherent
limitation of epidemiologic studies of time-dependent events
such as VAP.15
In conclusion, our findings suggest that VAP continues to
occur amidst lack of agreement regarding diagnostic criteria
and the exact prevalence. More importantly, VAP continues
to be associated with a statistically significant resource uti-
lization burden. Therefore, hospitals should attempt to target
patients at risk for VAP with cost-effective interventions
aimed at minimizing the occurrence of this complication.
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